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Résumé Abstract
Le test prénatal non-invasif (TPNI) reposant sur l’utilisation
de l’ADN fœtal libre (cffDNA) dans le sang maternel a été
introduit dans la pratique clinique dans de nombreux pays,
incluant le Canada. Ce test peut être effectué tôt durant la
grossesse pour détecter le syndrome de Down ainsi que
d’autres conditions. Bien que le TPNI promette de
nombreux avantages, il comporte aussi des enjeux
éthiques, légaux et sociaux (ELS). Cet article recense les
préoccupations qui se trouvent actuellement dans la
littérature sur les enjeux ELS du TPNI. Nous faisons quatre
observations. Tout d’abord, le TPNI semble exacerber
certaines des préoccupations existantes et soulevées par
d’autres tests prénataux (l’amniocentèse et le dépistage du
sérum maternel), telles que les menaces à l’autonomie
reproductive des femmes et la discrimination et la
stigmatisation potentielles des personnes handicapées et
de leurs familles. Cela peut être attribué à la probable mise
en œuvre en grande échelle et par la routinisation à venir
du TPNI. Deuxièmement, la distinction entre le TPNI
comme un test de dépistage (tel qu’il est actuellement
recommandé) et comme un test de diagnostic
(potentiellement dans le futur), présente certaines
implications sur la discussion des enjeux ELS.
Troisièmement, nous avons observé un changement
progressif dans la littérature. Celle-ci était à l’origine
composée d’analyses essentiellement conceptuelles, mais
recense maintenant un nombre croissant d’études
empiriques. Cela démontre la contribution des approches
de la bioéthique empirique alors que la technologie est en
cours d’implantation au sein de la pratique clinique. Enfin,
nous avons constaté un intérêt croissant pour les questions
de justice et d’équité en matière d’accès au TPNI dans la
mesure où le test devient implanté à une échelle plus
large.
Non-invasive prenatal testing (NIPT) using cell-free fetal
DNA (cffDNA) from maternal blood has recently entered
clinical practice in many countries, including Canada. This
test can be performed early during pregnancy to detect
Down syndrome and other conditions. While NIPT
promises numerous benefits, it also has challenging ethical,
legal and social implications (ELSI). This paper reviews
concerns currently found in the literature on the ELSI of
NIPT. We make four observations. First, NIPT seems to
exacerbate some of the already existing concerns raised by
other prenatal tests (amniocentesis and maternal serum
screening) such as threats to women’s reproductive
autonomy and the potential for discrimination and
stigmatization of disabled individuals and their families.
This may be due to the likely upcoming large scale
implementation and routinization of NIPT. Second, the
distinction between NIPT as a screening test (as it is
currently recommended) and as a diagnostic test
(potentially in the future), has certain implications for the
ELSI discussion. Third, we observed a progressive shift in
the literature from initially including mostly conceptual
analysis to an increasing number of empirical studies. This
demonstrates the contribution of empirical bioethics
approaches as the technology is being implemented into
clinical use. Finally, we noted an increasing interest in
equity and justice concerns regarding access to NIPT as it
becomes more widely implemented.
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Introduction 
Non-Invasive Prenatal Testing (NIPT) is a novel technology that allows the analysis of cell-free fetal
DNA (cffDNA) obtained from maternal plasma [1]. cffDNA can be detected as early as 7 weeks
gestation and its analysis – as early as 9 weeks – requires a simple blood draw from the pregnant
woman. NIPT is considered more reliable than current screening tests. It has better sensitivity (true
positive rate) and specificity (true negative rate) for the detection of aneuploidies (i.e., greater than
99% for trisomy 21 and about 97% for trisomy 13 and 18) and it produces fewer false positive results
[2,3]. At the same time, it is not yet sufficiently reliable to be considered as a diagnostic test. For this
reason, NIPT cannot yet fully replace diagnostic tests such as amniocentesis and chorionic villus
sampling (CVS) [4], which are still required for validating a positive NIPT result.
NIPT is currently being introduced into clinical practice in over 60 countries around the world [5]. It is
commercially available for the detection of trisomy 13, 16, 18, 21 and 22, for sex chromosome
abnormalities, fetal sex, RhD status, and specific microdeletions1 [7]. MaterniT21 was the first
commercially available test for trisomy 21 detection launched in 2011 by U.S.-based Sequenom, Inc.,
followed since by others companies such as Ariosa Diagnostics, Natera and Verinata Health [8].
1 Microdeletion is a chromosomal deletion [6] spanning several genes that is too small to be detected under the microscope
using conventional cytogenetic methods. 
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Professional societies recommend its use as a second-tier screening test only for pregnancies that
are identified as having an increased risk of fetal aneuploidies based on their initial screening test’s
results (Maternal Serum Screening or MSS) [9-11]. A clinical study partially sponsored by Sequenom
Inc. for NIPT validation in the low-risk population showed that its use for aneuploidy screening is
“likely to perform analytically as well in different risk groups of pregnant women” [12]. Other studies
have suggested that it could be used as a diagnostic test for single gene disorders [13] and that it
holds potential for fetal whole genome sequencing (FWGS) [14,15]. One of the latter studies related to
FWGS was partly funded by Sequenom, Inc. while the other includes an author who acts as a
consultant for Ariosa Diagnostics. The fact that NIPT research and development is being sponsored
and funded by industry creates an inherent conflict of interest that might bias research outcomes. For
instance, data publication and interpretation related to NIPT could emphasize the sensitivity and
specificity of the test while underrepresenting its limits, such as its positive predictive value or the
need to confirm a positive result with a diagnostic test [16]. These financial conflicts of interest can
compromise the integrity of research related to NIPT and therefore influence a patient’s decision-
making regarding the test. Moreover, some companies providing their own genetic counselling
services are being criticized for paying genetic counsellors who are advising patients on whether to
undergo testing [17]. Such situation raises concerns about the neutrality of counselling and the
patient’s informed decision.
With commercialization and progressing clinical implementation of NIPT, we have noticed that the
academic literature exploring the ethical, legal and social implications (ELSI) of NIPT has increased
significantly (Figure 1). 
Figure 1: Number of identified peer-reviewed papers addressing ELSI of NIPT
published every year between 2007 and 2015
NIPT’s implications at individual and societal levels were reported through a diversity of publications
such as empirical studies (qualitative and quantitative), conceptual analysis, and professional
guidelines. Authors from multiple backgrounds (e.g., physicians, genetic counsellors, gynecologists,
social scientists, disability rights and patient advocates) have discussed the implications of NIPT for
women and families, healthcare professionals, the healthcare system and society [18-28]. Questions
have been raised and discussed regarding the ways in which NIPT implementation should be handled
so as to be ethically sound and socially acceptable.
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This paper reviews the literature addressing the ELSIs associated with NIPT and presents benefits
and concerns found in this literature. These ELSIs are associated with three commonly discussed
features of NIPT: its capacity to provide genetic information early in the pregnancy (timing), the
simplicity of the procedure, which requires only a blood draw (ease), and the absence of an increased
risk of miscarriage (safety2). It is crucial to note, however, that the implications of these three features
– timing, ease and safety – are discussed in two different contexts. In the earlier days of NIPT,
following the first success in detecting and analyzing cffDNA (2007-2011), many believed it would be
introduced into clinical use as a diagnostic test. It was therefore compared to current diagnostic tests
and heralded as ‘safe’ and allowing earlier diagnosis [29,30].
Nevertheless, once data emerged showing that NIPT is not (yet) reliable enough to replace diagnostic
tests, it was gradually integrated into clinical use as a screening test [2]. This change in its ‘clinical
status’ was reflected by a change in the ELSI debate, as explained below. Although the nascent ELSI
literature regarding the use of NIPT as a screening test discusses similar benefits and concerns as
those related to its use as a diagnostic test [31], there are still significant differences. For example,
when a diagnostic test is required following NIPT as a screening test, the benefit of ‘earlier testing’ is
diminished [7,20] but the concern regarding NIPT becoming a one-step test is mitigated [7]. 
References in this review to the three features of NIPT (ease, safety, timing) thus relate both to the
early ELSI literature that considered it as diagnostic test and to the more recent literature that
considers it as a screening test, with appropriate specifications where necessary. The concerns that
relate specifically to NIPT as a diagnostic test are still relevant, since it is likely that in the future NIPT
will become sufficiently reliable to be used for diagnosis.
Methods
Objective
This paper aims to review benefits and concerns currently found in the literature on the ELSI of NIPT
based on a critical interpretive literature review [32]. This review is timely and can serve as a
foundation for researchers who wish to inform and contextualize their empirical and conceptual work
regarding NIPT.
Search methods
We searched three relevant databases: CINAHL, Medline and psycINFO. We also hand-searched for
further publications by first authors of well-cited papers, as well as highly relevant journals such as:
Prenatal Diagnosis, American Journal of Obstetrics and Gynecology, European Journal of Human
Genetics and Public Health Genomics. The search strategy was facilitated by using variant
terminology for the same keyword (e.g., cell free fetal DNA test and non-invasive prenatal test) and by
different combinations of those keywords. The combination of searched terms used was: (‘non-
invasive’ or ‘non invasive’) or/and (‘cell free fetal DNA’) or/and (‘prenatal’ or ‘antenatal’) and (‘testing’
or ‘screening’) or/and (‘ethics’ or ‘social’ or ‘legal’). 
Inclusion criteria and analysis
All abstracts were reviewed and the papers were judged eligible for inclusion if they focused on ethical
and/or social and/or legal implications of NIPT and if they were published between January 2007 and
April 2015. Reported studies could be conducted in any country, but had to be published in English or
French in peer-reviewed journals. One researcher, H.H., performed the search and the review: she
read the full text of each article, evaluated the relevance of retrieved papers, identified recurrent
2 In this paper, the terms ‘safety’ or ‘safe’ are used to underscore the fact that NIPT carries no increased risk of miscarriage.
By using these terms we do not imply that NIPT is free of any type of risk (such as increased anxiety) or that it cannot have
undesirable consequences at various levels.
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arguments related to the ELSIs of NIPT and grouped them under key themes. Two other researchers,
C.D. and V.R., read some of the papers and then all three (H.H., C.D. and V.R.) validated the coding
of the content by comparing and discussing the grouping of themes and their classification.
Discrepancies between different coding were discussed until a consensus was reached.
The structure of the review reflects the benefits and concerns observed in the literature, grouped
under four major themes: NIPT and reproductive autonomy; the routinization of NIPT and its impact
on decision-making and informed consent; social impact; and the implementation of NIPT. 
Findings
1. NIPT and reproductive autonomy
In allowing easier, safer and earlier testing, NIPT has often been portrayed as carrying great benefits
and as promoting reproductive autonomy. In the early papers that discussed it as a diagnostic test, it
was suggested that access to genetic information in the first trimester would allow women and their
families more time to make a decision regarding their pregnancy management: to prepare for the birth
of a child with special needs or to make a decision regarding termination of pregnancy [33]. For those
who decided to terminate, NIPT would allow an earlier termination, making it medically safer and
allowing it to occur when maternal-fetal attachment might be less established and when the
pregnancy was not yet socially visible [27,34]. 
While the earlier timing of NIPT as a diagnostic test was mostly heralded as a great benefit, some
authors pointed out that it might also have adverse effects by increasing the burden of choice
imposed on women and so generate additional anxiety [25, 33]. Pregnancies involving fetuses with
genetic abnormalities sometimes end in spontaneous abortion. While some women would prefer to
avoid the trauma of a miscarriage, even if doing so means requesting an abortion, for others, the
earlier testing by NIPT could transform the ‘natural phenomenon’ of spontaneous abortion, over which
women have no control, into the result of a deliberate and voluntary choice [35]. For some women,
earlier testing with NIPT would therefore increase the pressure on them to make excruciating
decisions that were previously unnecessary, potentially turning the expanded ‘reproductive autonomy’
offered by the test into a heavy moral burden [36].
As the development of NIPT technology progressed it became clear that NIPT should be considered a
screening test and that a positive result requires confirmation through invasive testing, which limited
the discussion of benefits on those receiving a negative result. NIPT’s main advantage as a screening
test was thus seen as its higher reliability in comparison to previous screening tests. Women who
screen as high-risk can turn to NIPT rather than proceed straight to diagnostic testing. For most of
these women, a negative NIPT result would be reassuring enough to allow them to refrain from further
invasive testing and its associated risks [20,27]. Thus, by providing a new option, NIPT was seen as
promoting reproductive autonomy by allowing women access to more reliable results without an
increased risk of miscarriage.
2. The routinization of NIPT: Impact on decision-making and informed consent
The early papers that discussed NIPT as a diagnostic test raised concerns that the test would be
offered to all pregnant women as a routine part of pregnancy care, and would thus be perceived by
women as “just another blood test”, without a full understanding of its meaning and potential
impact [7]. Since routinization is associated with lower rates of informed choice [37], it was feared that
decision-making would be undermined and that pressure to test would increase [27,38]. In the context
of invasive testing (e.g., amniocentesis), the decision not to test could be ‘justified’ by the wish to
avoid an increased risk of miscarriage. By removing this ‘socially acceptable’ justification, it was
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argued that NIPT significantly modified the decision-making context and might increase the pressure
on women by leaving them with “no reasonable argument” for rejecting the test [27,33,34,36,39].
The potential routinization of NIPT could erode informed consent procedures [28,37,40-42]. Empirical
studies have shown that due to the safety of the test, the consent process for NIPT (including written
consent) is viewed, overall, as less important than for invasive testing [28,43]. However, Silcock and
colleagues’ study reveals that women considered a greater need for written consent (87% of women
believed written consent is required for NIPT compared with 97% for invasive diagnostic tests) than
health professionals (78% of health professionals believed written consent is required for NIPT
compared with 97% for invasive diagnostic tests). The authors noted that “it was difficult to know if
they [women] were stating what they thought was expected of them, or saw written consent as an
important element of decision-making” and thus they called for exploratory research in this area. This
discrepancy is also a potential source of ethical concern given the unequal power relationship
between patients and health professionals regarding the information that should be shared with
women to ensure their consent is informed. For example, while women might consider a written
consent as a tool offering more information about the test, professionals might view it as a legal
protection ensuring the woman’s documented agreement or disagreement to take the test [28].
The perception of written consent as less important for NIPT than for invasive testing may in the long
term undermine informed decision-making and reproductive autonomy because women, their partners
and health professionals may not give as much thought to the potential implications of a safe blood
test compared to an invasive test. As Silcock and colleagues recently suggested: “written informed
consent may help the test stand out from routine blood tests and encourage fuller discussion of the
implications” [28]. 
NIPT was also described as posing new challenges related to genetic counselling. It was argued that
if NIPT were to be offered to all pregnant women (high and average risks), the counselling demand
could not be met with current limited resources [5,44] and that such demand would be prohibitively
burdensome for a public healthcare system operating within budget limits [7]. On the other hand, it is
suggested that NIPT will facilitate pre-test counselling discussion since it would not require the
complex explanation of miscarriage risk [34] and understanding probabilities [36]. Some expressed
concerns that a simple blood test, if performed on the same day as pre-test counselling, would only
allow a short time frame for reflection and might result in rushed and uninformed decisions. It was
thus argued that NIPT should be offered and performed on two different days, to allow appropriate
pre-test counselling and reflection [45]. However, empirical studies showed that some women prefer
to make a decision about NIPT at the same appointment at which it is offered [27,28], leading to a
rushed decision-making process that might undermine informed choice [43].
3. Social impact of NIPT
The potential high uptake of NIPT [46,47] raised concerns addressed by different authors related to
the reasons for which individuals would wish to test and the social impact of such individual
decisions [48,49]. The main concerns in this context are the possible lowering of the threshold of
testing and the risk of increased stigmatization and discrimination against individuals with disabilities
and their families, as well as the resurgence of eugenic social attitudes.
Lowering the threshold of testing and pregnancy termination 
While the invasiveness and risk of miscarriage associated with current diagnostic testing prevent the
expansion of its uptake for a wider range of conditions, NIPT’s capacity to offer genetic information in
a safe and easy manner is anticipated to lower the threshold of testing, i.e., to encourage women to
consider prenatal testing as appropriate for less severe conditions and even for non-medical
reasons [34,50,51]. It is thus argued that in the future, expanding the scope of NIPT could generate
large amounts of information regarding late onset diseases (e.g., Huntington’s), predispositions to
severe and common diseases (e.g., breast cancer and diabetes), minor abnormalities [52-54], and
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even non-medical information (e.g., paternity) and physical traits (e.g., eye colour). While such an
expansion of testing may promote women’s and couples’ reproductive autonomy by offering access to
more information, it also introduces two concerns. First, an avalanche of genetic information that is
difficult to interpret and explain, some of it of unknown significance, leading to confusion on the part of
couples and health professionals [21,29]. Second, in cases where NIPT does not lead to termination
of the pregnancy, the extensive genetic information about the fetus can become a threat to the
resulting child’s privacy. Some have argued that testing purely for information (without any intention to
terminate) for a range of conditions – such as adult-onset diseases – would be wrong because it could
impede the child’s future choices (i.e., “right to an open future”), and also to some extent create harm,
since “the child may feel greater anxiety knowing he faces a future with a particular condition” [55].
As a further complication, increased information might ultimately result in an increase in the volume of
terminations [27,56,57] as well as its ‘trivialization’, i.e., termination of pregnancies for minor or
unimportant reasons [29,45,58-60]. As mentioned previously, the earlier women have access to
diagnostic information, the earlier they can make a decision and proceed to termination when it is
medically safer and potentially less psychologically traumatic [27,45,61]. For instance, in cases where
NIPT reveals a very high risk of Huntington’s disease, women who would not terminate a pregnancy
in the second trimester might decide to do so in the first trimester, even if NIPT had not yet been
validated as diagnostic [45]. Moreover, the possibility of earlier and safer testing for non-medical traits,
such as the sex of the fetus, could lead to an increase in ethically controversial selective
abortions [53,58,62,63].
 
Discrimination, stigmatization and eugenic attitudes
In the long term, the large-scale implementation of NIPT and its potential validation as a diagnostic
test could result in an increase in both the detection of an important number of fetal conditions and in
termination rates [5,63], thereby substantially reducing the prevalence of certain conditions in
society [64]. While this eventuality carries public health benefits by reducing high costs of care for
people with disabilities such as Down Syndrome [24], it is argued that it could also increase the
stigmatization of and discrimination against individuals living with these conditions and their
families [24,44,65]. For instance, mothers of children with Down syndrome have expressed worries
about a decrease in social acceptance of people with Down syndrome and thus a decrease in the
investment of resources and support for affected individuals and their families [22,44,45,66]. This
might also negatively impact research efforts that focus on the development of treatments for
conditions such as Down Syndrome [57]. There are concerns that the availability of NIPT would result
in social pressure as well as stigmatization of those women who decide to continue an affected
pregnancy, because conditions that would be detectable by NIPT would be perceived as “easily
avoidable” [27,35].
Lowering the threshold of testing and the trivialization of pregnancy termination might lead to
changing expectations about what people “should do” when NIPT reveals genetic abnormalities in the
foetus, or even ‘socially undesirable’ traits [67]. Concerns are therefore expressed about NIPT paving
the road to a “quest for a perfect baby”, progressively creating new forms of eugenics in
society [68,69]. Empirical studies show that people are concerned about eugenic behaviours resulting
from increased stigmatization and discrimination against disabled people following the large-scale
implementation of NIPT [70]. Potential future use of NIPT for fetal whole-genome sequencing (WGS)
and the increase in the amount of genetic information obtained from the fetus exacerbate such
concerns.
In order to ensure an ethically sound implementation of NIPT – and possibly Non-Invasive Prenatal
Diagnosis (NIPD) in the future – and to avoid a slippery slope towards eugenics, it has been
suggested that such issues must be discussed in the public arena [60]. Each step towards increased
control over human reproduction should be addressed adequately to prevent possible conflicts with
social values [65]. However, while concerns regarding a resurgence of eugenic ideas and practices
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are articulated, it is also argued that Western societies already have numerous policies and
regulations – for instance, relating to respect of individual choices or the rights of disabled individuals
– that can help prevent a radical eugenic drift [67].
4. The implementation of NIPT
Legal and regulatory issues related to NIPT implementation
NIPT technology innovation, quality, cost and availability are all closely linked to patenting and
intellectual property issues. Currently, there are hundreds of patents related to cffDNA testing, with
some of them already granted and others pending. Since 2011, four companies in the US (Sequenom,
Verinata Health, Ariosa and Natera) have been locked in patent litigation [71]. Early in December
2014, Illumina (parent company of Verinata Health) and Sequenom settled their patent and intellectual
property dispute and agreed to pool their NIPT patents [72]. While other disputes are ongoing (e.g.,
Ariosa vs. Sequenom), and might take time to resolve, concerns are raised that one company might
secure market monopoly [71]. In such a case, the company that prevails could prevent competitors
from developing and providing the test, which may result in an increase in price, in lower availability
and access, as well as limited research aimed at developing NIPT technology [73]. 
The clinical introduction of NIPT has stimulated discussions regarding equity of access, arising both
from the commercial/private implementation and its potential public funding. In the absence of public
universal coverage, NIPT will be accessible only to those who are able to afford it, exacerbating
inequalities in access to the test [5,7] and socioeconomic stratification. Indeed, NIPT could become a
‘reproductive strategy’ that is available to a privileged portion of the population, allowing certain
parents to ‘choose’ the best genetic characteristics for their children [29]. In a study performed by
Yotsumoto and colleagues to assess pregnant women and health professionals’ attitudes toward
NIPT, pregnant women expressed worries about the possibility of unequal access to NIPT due to its
high cost, especially in a context where it would be offered by private companies and not covered by
public funding [62,74]. The ELSI literature has frequently called for policies that support equity in
access to NIPT in various countries [5,75].
The promotion of NIPT by private companies
The aggressive advertising of NIPT by private companies, as well as its introduction prior to the
publication of professional guidelines, created some confusion regarding how to best incorporate
NIPT into clinical practice [8,16]. For instance, the fact that its imperfect specificity, sensitivity and
positive predictive value cannot validate it as diagnostic was arguably minimized when different
companies rushed to capture a market share [8]. Consequently, potential benefits for women and
families were over-estimated. Moreover, direct-to-consumer (DTC) commercial offer of NIPT is
considered by several authors to be a potential threat to an ethical implementation of this
test [7,49,50]. Health professionals do not recommend this type of marketing for NIPT, arguing that
women and couples may not have access to suitable information, counselling and support to guide
their decision-making [25,50].
Challenges for NIPT implementation in a public healthcare system
In several countries (e.g., Canada, UK, France), prenatal screening for fetal abnormalities (e.g.,
trisomy 21) is offered to pregnant women as part of publicly funded programs. The chief purpose of
such programs is to “enable meaningful reproductive choice with regard to parenting or avoiding a
child with a serious disorder or disability” [76]. For the time being, NIPT’s clinical introduction is left to
commercial companies that are offering their test through health professionals without the
involvement of governments or public health agencies [7]. 
However, implementing NIPT into public health programs would raise several challenges related to
the availability of budgetary [77,78] and personnel resources [53]. For instance, if and when NIPT is
validated for use by all pregnant women (high and average risk), challenges will be introduced
regarding the coverage within the available limited budget in order to ensure equity of access [7].
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Another barrier will be the scarce resources of available health professionals (e.g., genetic
counsellors) to meet an increased demand for counselling [5]. The rapid technological advancement
and future expansion in scope of the conditions that NIPT can detect may further complicate matters.
If NIPT is introduced into a public healthcare system, questions will arise regarding which conditions
should be covered, for whom, who should make these decisions and how [50,79]. 
Cost-benefit analyses must be nuanced because universal accessibility would be costly for a public
healthcare system. For instance, the Canadian Agency for Drugs and Technologies in Health
(CADTH) released a report reviewing the cost-effectiveness of NIPT in several countries (US,
Australia, Canada) and the key findings were that “at the present time, universal screening with NIPT
appears to increase costs substantially and is unlikely to be feasible. However, the use of NIPT in
contingent screening, where only a certain proportion of pregnant women determined by the degree of
risk receive NIPT, may be feasible” [77]. 
Some authors argued that public health care systems need to consider the cost implications of
offering tests that will not change pregnancy management [19] and the impact of implementing testing
“for information only” (with no intention to terminate) [34,51]. Such debates are clearly ethically
sensitive because they imply a certain interference with women’s reproductive autonomy and free
choice regarding why they want information and how they will manage their pregnancy based on a
(potentially) positive result from the test. Thus, important questions remain to be answered about
whether public funding of NIPT represents a good use of scarce resources in a public healthcare
system [54]. 
The NIPT ELSI literature has also argued that decision-making by governmental agencies, public and
private insurers, research institutions and biotechnology companies regarding investment in research
and coverage of NIPT should take into consideration the values, opinions and preferences of various
stakeholders (e.g., families, healthcare providers, professional societies, and representatives of civil
society such as community activists) [19]. It has been suggested that guidelines, policies and
regulations be developed by professional societies, health agencies and the government to promote
an ethically sound implementation of NIPT [50], one that is not governed merely by market
pressures [71].
Discussion
The ELSI literature regarding NIPT discusses benefits and concerns that are similar to those
introduced by other prenatal tests, such as amniocentesis and serum screening. Challenges
regarding informed consent, informed decision-making, potential routinization, trivialization of
termination, lowering the threshold of testing, genetic counselling, eugenics, discrimination against
people with disabilities and equity of access to the test [44, 45] are not novel. Yet, NIPT seems to
exacerbate some of these issues. While the unique features of the test (safety, ease and earlier
timing) potentially represent important clinical benefits, the large scale introduction of NIPT might
promote certain negative effects of routinization by increasing test uptake and therefore termination
rates [5,63], which might in turn lead to discrimination and stigmatisation of people living with
disabilities and their families.
Moreover, as the technology advances, we observed that the ELSI debate has been influenced by the
shift in NIPT’s clinical status from being perceived as a ‘diagnostic’ test (NIPD) to being introduced as
a ‘screening’ test (NIPT/NIPS). Whereas the abovementioned concerns were very prevalent in the
“NIPD-days” – and are still tackled in the current literature on NIPT – other concerns now seem to
garner more attention with the widespread introduction of NIPT, such as the equity of access that
emerged as a frequent challenge for an appropriate clinical introduction of the test [5,7,80].
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In the literature published between 2007 and 2015, we observed that the debate around NIPT
generally moved from being mostly conceptual to more empirical. This move might be explained in
various ways: the conceptual work may have informed the design of the empirical studies; the
empirical work appeared later on, due to the time it takes to set up and conduct empirical projects;
and funding opportunities for empirical work may have been delayed based on the ongoing
recognition and presence of NIPT in clinical practice.3 Moreover, empirical studies (using qualitative or
quantitative methods) were needed to assess views, preferences, attitudes and needs of pregnant
women, partners and health professionals and to inform the conceptual ELSI debate surrounding this
recent technology. Therefore, such studies were and are still performed in many countries, such as
the Netherlands [20], the US [21], the UK [27,34], Hong Kong [42], and Japan [62]. Results showed
overall positive attitudes regarding NIPT [20,25,27,81], with women and partners valuing mostly the
safety of the test and health professionals its accuracy [25,34]. They also demonstrated the important
contribution of the empirical work to the normative debate around NIPT. For instance, empirical
studies provided evidence of the concerns that were raised in the conceptual literature, confirming the
early concerns about the challenges to meet an appropriate level of informed consent in the context of
NIPT [28,43]. Empirical studies can also inform the development of public policies and guide the
development of an infrastructure for NIPT’s clinical implementation [7]. 
It is expected that in the coming years, NIPT will be used to screen for a wide-range of fetal
conditions, including childhood disorders and late-onset diseases. Inevitably, this raises questions
regarding the expansion in scope of prenatal testing associated with the rights of the future child [55].
What conditions should be tested? What information can be harmful to the child? And who decides?
These questions need further research and debate. As NIPT implementation expands, challenges
should be debated by all stakeholders – including professional societies, health ministries, public and
private insurance providers, patients and clinicians – in order to guide the development of NIPT
practice guidelines and policy and so ensure that it is used in an ethically and socially acceptable
manner.
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